Radioiodine Therapy for Juvenile Graves’ Disease: A Single Institution Experience in Japan (Poster 317) | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Abstracts & Posters

Radioiodine Therapy for Juvenile Graves’ Disease: A Single Institution Experience in Japan (Poster 317)

key information

source: Thyroid

year: 2018

authors: T. Mizokami, K. Hamada, T. Maruta, K. Higashi, J. Tajiri

summary/abstract:

131I radioiodine therapy (RIT) has been applied for juvenile Graves’ disease (GD) in the United States for a long time. However, RIT for juvenile GD has been avoided because of the potential risk of tumorigenesis in Japan. There have been few reports regarding RIT for juvenile GD in Japan. Therefore, we reviewed juvenile GD patients treated with RIT in our thyroid specialty clinic.

We reviewed the medical records of 493 GD patients under the age of 19 who had visited our clinic between January 2000 and December 2016. Each RIT was performed as an outpatient treatment, and the maximum 131I dose was 481 MBq per treatment. One hundred and eleven juvenile GD patients (22 males and 89 females: 10 to 18 years old, median 16 years) underwent RIT. 131I administration was performed once in 83 patients, twice in 25 patients, and three times in 3 patients. The total 131I dose was 133-1,143 MBq (median 481 MBq). The duration of follow-up after the initial RIT ranged from 12–201 months (median 80 months).

organization: Tajiri Thyroid Clinic, Japan